{"filing":{"accession_number":"0001437749-26-031283","cik":"0000039368","ticker":"FUL","company_name":"FULLER H B CO","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-23","primary_document":"ful20260925_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/39368/000143774926031283/ful20260925_8k.htm"},"events":[{"id":35348,"run_id":32554,"accession_number":"0001437749-26-031283","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses two events: Ruth S. Kimmelshue's resignation as a director effective immediately, and R. Jeffrey Bailly's election to the Board as a Class I director effective September 23, 2026. While both a departure and an appointment occur, the principal disclosed action centers on Bailly's appointment, which is emphasized throughout the filing and press release as bringing \"highly relevant operating and leadership experience\" and \"valuable expertise in medical technologies\" to support the Company's strategic repositioning. The appointment is material to investors as it reflects a deliberate Board composition change aligned with the Company's strategic priorities.","company_name":"FULLER H B CO","ticker":"FUL","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39370,"accession_number":"0001437749-26-031283","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two events: Ruth S. Kimmelshue's resignation as a director effective immediately, and R. Jeffrey Bailly's election to the Board as a Class I director effective September 23, 2026. While both a departure and an appointment occur, the principal disclosed action centers on Bailly's appointment, which is emphasized throughout the filing and press release as bringing \"highly relevant operating and leadership experience\" and \"valuable expertise in medical technologies\" to support the Company's strategic repositioning. The appointment is material to investors as it reflects a deliberate Board composition change aligned with the Company's strategic priorities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:50:44.550064+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39370,"accession_number":"0001437749-26-031283","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two events: Ruth S. Kimmelshue's resignation as a director effective immediately, and R. Jeffrey Bailly's election to the Board as a Class I director effective September 23, 2026. While both a departure and an appointment occur, the principal disclosed action centers on Bailly's appointment, which is emphasized throughout the filing and press release as bringing \"highly relevant operating and leadership experience\" and \"valuable expertise in medical technologies\" to support the Company's strategic repositioning. The appointment is material to investors as it reflects a deliberate Board composition change aligned with the Company's strategic priorities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:50:44.550064+00:00","company_name":"FULLER H B CO","ticker":"FUL","filing_date":"2026-09-28"}]}